Capital Expenditures - Nektar Therapeutics (NASDAQ:NKTR) - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 1.5 USD -8.54%

Updated:

Nektar Therapeutics
Capital Expenditures

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

TTM

|

Adjust for Inflation

Nektar Therapeutics
Capital Expenditures Peer Comparison

JNJ

BMY

PFE

MRK

LLY

Company		Capital Expenditures	CAGR 3Y	CAGR 5Y	CAGR 10Y
	Nektar Therapeutics NASDAQ:NKTR	Capital Expenditures -$622k	CAGR 3-Years 59%	CAGR 5-Years 49%	CAGR 10-Years 23%
	Johnson & Johnson NYSE:JNJ	Capital Expenditures -$4.5B	CAGR 3-Years -10%	CAGR 5-Years -4%	CAGR 10-Years -2%
	Bristol-Myers Squibb Co NYSE:BMY	Capital Expenditures -$1.2B	CAGR 3-Years -18%	CAGR 5-Years -6%	CAGR 10-Years -8%
	Pfizer Inc NYSE:PFE	Capital Expenditures -$3.5B	CAGR 3-Years -7%	CAGR 5-Years -7%	CAGR 10-Years -9%
	Merck & Co Inc NYSE:MRK	Capital Expenditures -$3.7B	CAGR 3-Years 7%	CAGR 5-Years -6%	CAGR 10-Years -10%
	Eli Lilly and Co NYSE:LLY	Capital Expenditures -$7.6B	CAGR 3-Years -50%	CAGR 5-Years -19%	CAGR 10-Years -21%

See Also

Based on the financial report for Mar 31, 2024, Nektar Therapeutics's Capital Expenditures amounts to -622k USD.

Over the last year, the Capital Expenditures growth was 67%. The average annual Capital Expenditures growth rates for Nektar Therapeutics have been 59% over the past three years , 49% over the past five years , and 23% over the past ten years .

Join more than 141,700+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.